


Supplemental Table S1. Clinical characteristics, vaccination, humoral response, and tolerability post Tixagevimab and Cilgavimab.

Age/Gender	Ethnicity	Diagnosis	Immunosuppression	No. vaccine doses pre-T+C	Pre-T+C RBD (BAU/mL)	Post-T+C RBD (BAU/mL)	Pre-T+C ACE2 vs. BA.5	Post-T+C ACE2 vs. BA.5	Breakthrough ^{^^} COVID-19 (post T+C)	Reactogenicity/ Adverse events
51/F	White	IA [†] Multiple sclerosis	Prednisone Rituximab	3 (MMM [§])	9	2659	0%	0%	No	No/ No
64/F	White	IA [†]	MMF [‡] Adalimumab	3 (PPP [§])	8	5633	0%	10%	No	No/No
52/F	White	IA [†]	Azathioprine	3 (PPP [§])	265	4749	0%	14%	No	No/ Flare ^{**}
38/F	White	SLE [^]	Hydroxychloroquine IVIG MMF [‡] Rituximab	3 (MMM [§])	2042	6386	7%	15%	No	No/No
51/M*	White	Anti-synthetase syndrome	IVIG MMF [‡] Rituximab	3 (MMM [§])	2576	4453	7%	17%	No	No/No
38/F	White	IBD [§]	Etanercept	3 (PPP [§])	822	7490	0%	23%	No	No/No
66/F	White	IA [†] Sjögren's	Adalimumab HCQ Sulfasalazine	4 (PPMP [§])	966	7737	0%	26%	No	No/No
49/F	White	SLE [^] Sjögren's	Belimumab MMF [‡]	5 (PPPPP [§])	6586	8731	14%	28%	No	Injection site pain (mild) Fatigue (mild)/No
75/F*	White	Autoimmune hepatitis	MMF [‡]	4 (MMMM [§])	4154	9344	20%	35%	Yes: 106 days post T+C ^{§§}	No/No
51/F	White	IA [†] Multiple Sclerosis	Rituximab	3 (PPP [§])	861	5172	20%	36%	No	No/No
57/F	Asian	Relapsing polychondritis	Methotrexate Prednisone Tocilizumab	4 (PPPP [§])	2471	8989	14%	46%	Yes: 194 days post T+C ^{§§}	No/No

*indicates two separate 150 mg+150 mg doses; †Denotes rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or inflammatory bowel disease associated arthritis; ^Systemic lupus erythematosus; § Inflammatory bowel disease; \$ M indicates mRNA-1273/; P indicates BNT162b2; §Flare occurred at days 30 and 60 post-T+C respectively; ‡ Mycophenolate mofetil or mycophenolic acid; **Flare occurred at day-60 post T+C and required treatment with 7-day course of oral glucocorticoids; ^^ SARS-CoV-2 infection occurring at least 14 days following primary vaccination.



Supplementary Fig. S1. Anti-RBD response (WHO BAU) pre-and post-Tixagevimab and Cilgavimab in 11 vaccinated patients with autoimmune diseases.